News und Analysen

Dividend Kings are among the most steady corporations on the market. While many businesses don't even last a decade, these companies have survived and thrived and raised their payouts for at least

In the often-volatile world of biotech stocks, shares of small-cap Blueprint Medicines (NASDAQ: BPMC) have proven surprisingly steady over the past 12 months. But the stock could be gearing up for a

CVS Health (NYSE: CVS) is a busy company. It runs the nation's largest drugstore chain with nearly 10,000 locations; it also manages prescription drug plans for employers and insurers; and, through

A struggling economy and a bear market haven't been able to stop Vertex Pharmaceuticals (NASDAQ: VRTX). Over the past year, the company's shares are up by 17%. And Wall Street continues to be

People saving for retirement often dream of crossing the $1 million milestone. While it is far from obvious that this amount is enough to live out the rest of one's life comfortably, it is still a

Decisions, decisions. Every investor has to make them. The good news is that some decisions aren't difficult. Three Motley Fool contributors identified dividend stocks that should be easy buy

Medtronic (NYSE: MDT) has grown revenue over the years thanks to its solid portfolio of medical devices. The company sells devices worldwide in the areas of diabetes, cardiovascular, neuroscience

Shares of BioNTech (NASDAQ: BNTX) were up as by much as 5.3% on Friday before closing the session up 3.85% after the biotech company announced positive news regarding a clinical trial for its

Shares of Apollomics (NASDAQ: APLM) were up more than 11% Friday morning after an analyst initiated coverage on the stock with a buy rating. The clinical-stage biopharmaceutical company focuses on

Victoria's Secret (NYSE: VSCO) shareholders lost ground to the market this week. Shares fell 14% through Thursday trading, compared to a 0.4% increase in the S&P 500. This drop added to a tough year

Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The

Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. That's equivalent to a $7 billion drop in market capitalization. 

What's

Biotech pioneer Amgen (NASDAQ: AMGN) has several key elements of a good dividend stock. The company has raised its payout for 12 straight years, free cash flows have remained steady at a little over

Imagine spending a lifetime building your investment portfolio only to worry about whether you will outlive the balance in your investment accounts.

If you are exclusively buying growth stocks with

Regardless of your investing experience or risk tolerance, putting cash into stocks takes a certain tolerance for volatility and uncertainty. No investment has a guaranteed outcome. However, if you

Shares of Sarepta Therapeutics (NASDAQ: SRPT) nosedived last week as the Food and Drug Administration (FDA) did not approve the company's gene therapy treatment, SRP-9001. Panic has been setting in

Not for the first time this year, Horizon Technology Finance (NASDAQ: HRZN) is tapping the public markets for a fresh round of capital-raising. Investors clearly didn't consider that to be good

Shares of pharma titan Pfizer (NYSE: PFE) were up by 2.24% on moderate volume as of 2:29 p.m. ET Wednesday afternoon. The drugmaker's stock is trending higher despite every major U.S. stock index